Guardant Health announced a partnership with the Agostino Gemelli University Polyclinic Foundation IRCCS to establish an in-house liquid biopsy testing service as a part of its diagnostics services within its hospital system. Leveraging Guardant Health’s cutting-edge proprietary digital sequencing platform, this initiative will include on-site analysis of Guardant360 CDx liquid biopsy tests directly within the Policlinico Gemelli facilities in Rome, Italy. The partnership will serve clinical research and patient care needs, marking a significant milestone as one of the first dedicated liquid biopsy testing facilities in Italy housed within a hospital system. This collaboration underscores Guardant Health’s commitment to expanding access to innovative cancer diagnostics and improving patient outcomes globally. Policlinico Gemelli, one of Italy’s largest and most renowned hospitals, serves thousands of cancer patients each year at its comprehensive cancer center. The facility is known for its advanced oncology services, including diagnostics, treatment, and research.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health management to meet with Craig-Hallum
- Boeing’s Starliner to return without astronauts: Morning Buzz
- Guardant Health enters open market sale agreement for up to $400M in stock
- Guardant Health price target raised to $40 from $32 at UBS
- Guardant Health price target raised to $34 from $30 at Piper Sandler